ImmuCell Corporation ICCC
9.93
(0.04)
(0.40%)
as of 25 Sep
- Market cap
- $90.6M
- P/E
- 117×
Follow ICCC
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
8.27% | (3.81%) | (1.88%) | 2.57% | |
| 5.15% | (2.37%) | (1.22%) | 1.69% | ||
ROIC |
4.11% | 3.19% | 5.04% | 7.84% | |
Return on Tangible Assets |
6.25% | (3.05%) | (1.53%) | 2.09% | |
Average Days of Receivables |
33.58 | 45.14 | 32.85 | 34.47 | |
Free Cash Flow per Share |
0.08 | 0.14 | 0.38 | 0.47 | |
Free Cash Flow |
0.75 | 1.26 | 3.42 | 4.23 | |
Capital Expenditures |
(1.24) | (1.21) | (1.05) | (1.66) | |
Piotroski F-Score |
7.00 | 7.00 | 6.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
4.61% | 6.19% | 10.02% | 12.14% | |
Accounts Receivable Turnover |
11.42 | 7.69 | 9.91 | 11.63 | |
Accounts Payable Turnover |
6.79 | 6.80 | 8.25 | 6.79 | |
Inventory Turnover |
1.90 | 1.98 | 2.14 | 2.11 | |
Average Days of Payables |
51.71 | 51.43 | 46.64 | 55.98 | |
Days of Inventory on Hand |
218.12 | 208.82 | 184.22 | 181.00 | |
Tax Rate |
(0.01) | 0.01 | 0.04 | (0.08) | |
Research and Development Expense of Revenue |
11.17% | 11.00% | 8.70% | 6.16% | |
Selling, General and Administrative Expense of Revenue |
21.37% | 24.43% | 25.54% | 28.07% | |
Share Based Compensation of Revenue |
0.94% | 1.07% | 1.27% | 1.81% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | (2.38) | (8.21) | 7.48 | |
Depreciation/Fixed assets |
0.11 | 0.13 | 0.13 | 0.12 | |
Capex/Depreciation |
(0.45) | (0.44) | (0.40) | (0.69) | |
Revenue per Share |
3.07 | 3.06 | 3.31 | 3.38 | |
Operating CF per Share |
0.22 | 0.27 | 0.49 | 0.65 | |
Capex per Share |
(0.14) | (0.13) | (0.12) | (0.18) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.05 | |
Net Profit Margin |
8.37% | (3.76%) | (1.82%) | 2.57% |
Columns are period end dates